Menu
Recruiting NCT06831253

Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome

No phase Interventional Severe Dry Eye Syndromes Dry Eye Syndromes

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: injections of Platelet-Rich Plasma in lacrimal gland.
Who it may be relevant to
Registry conditions: Severe Dry Eye Syndromes, Dry Eye Syndromes. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Efficacy of Restoration of Lacrimal Secretion After Injection of Platelet-Rich Plasma (PRP) Into the Lacrimal Gland in Severe Dry Eye Syndromes (ReLIPSSO)

Overview

The investigatror wants to show the efficacy of Platelet-Rich Plasma injection in lacrimal gland to restore the lacrimal secretion in patients presenting aqueous deficiency reponsible for severe dry eye syndrome.

Detailed description

injections in lacrimal gland four times during the study for each patient

Interventions

  • Other injections of Platelet-Rich Plasma in lacrimal gland
    injections of Platelet-Rich Plasma in lacrimal gland

Primary outcome measures

  • To compare the lacrimal secretion after 4 monthly injections of PRP into the lacrimal gland [Time frame: week 16]
Secondary outcome measures (1)
  • To compare the different clinical follow-up parameters of qualitative dry ocular syndrome and quantitative after 4 monthly injections of PRP into the lacrimal gland [Time frame: week 16]

Eligibility criteria

Inclusion criteria

  • Platelet counts, and clotting factors in the standarts
  • Presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist

Exclusion criteria

  • Patients with significant fibrosis of the conjunctival portion of the lacrimal gland
  • Patients with complete stenosis of both lacrimal meatus in the treated eye

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • CHU de Nice — Nice

Identifiers

NCT: NCT06831253 · 24-AOIP-02 · IDRCB

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗